A-1331852

CAS No. 1430844-80-6

A-1331852 ( A1331852;A 1331852 )

Catalog No. M11823 CAS No. 1430844-80-6

A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 59 In Stock
5MG 105 In Stock
10MG 168 In Stock
25MG 348 In Stock
50MG 521 In Stock
100MG 745 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    A-1331852
  • Note
    Research use only, not for human use.
  • Brief Description
    A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).
  • Description
    A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM); selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells (Molt-4 viability IC50=6 nM); demonstrates antitumor efficacy in the Molt-4 xenograft model; orally active.
  • Synonyms
    A1331852;A 1331852
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2;Bcl-w;Bcl-xL;Mcl-1
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    1430844-80-6
  • Formula Weight
    658.81
  • Molecular Formula
    C38H38N6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 12 mg/mL
  • SMILES
    CC1=C(C=NN1CC23CC4CC(C2)CC(C4)C3)C5=C(N=C(C=C5)N6CCC7=CC=CC(=C7C6)C(=O)NC8=NC9=CC=CC=C9S8)C(=O)O
  • Chemical Name
    2-Pyridinecarboxylic acid, 6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Leverson JD, et al. Sci Transl Med. 2015 Mar 18;7(279):279ra40.
2. Punnoose EA, et al. Mol Cancer Ther. 2016 May;15(5):1132-44.
3. Lucas CM, et al. Leukemia. 2016 Jun;30(6):1273-81.
molnova catalog
related products
  • BTSA1

    BTSA1 is a BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis.

  • Bcl-xL antagonist 2

    Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.

  • Orobol

    Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.